---

Sexual Dysfunction: Yellow Card Scheme

Answer

A total of 52 reports that describe increased sexual arousal suspected to be associated with the use of medicines or vaccines have been received through the Yellow Card scheme. The reports were received between 2014 and 2025 for a wide range of medicinal products which include antidepressants, hormonal medicines, vaccines, antipsychotics, antibiotics, cardiovascular medicines, drugs used to treat attention deficit hyperactivity disorder, sedatives, drugs used to treat dementia and diabetes, and single reports for drugs used to treat osteoporosis, Parkinson’s disease, and pain.

The term increased sexual arousal itself is not in the product information for any of the above classes of medicines, however terms such as increased libido and hypersexuality are reflected in product information for medicines used to treat Parkinson’s disease. The following table shows a breakdown of all spontaneous Yellow Card Reports the Medicines and Healthcare products Regulatory Agency (MHRA) received from 1 January 2014 to 4 November 2025, where the MedDRA, a categorisation of medical terminology, Lowest Level Term (LTT) ‘increased sexual arousal’ was reported:

Year	Number of reports
2014	1
2015	1
2016	6
2017	4
2018	1
2019	4
2020	6
2021	14
2022	5
2023	4
2024	1
2025	5
of	52

In addition, the following able shows a breakdown of all spontaneous Yellow Card Reports the MHRA received from 1 January 2014 to 4 November 2025 where the MedDRA LLT ‘increased sexual arousal’ was reported, broken down by substance:

Year	Substance	Number of reports
2014	TRAZODONE	1
2015	CITALOPRAM	1
	PROPRANOLOL	1
2016	AMOXYCILLIN	1
	ARIPIPRAZOLE	1
	CLAVULANIC ACID	1
	ETHINYLESTRADIOL	1
	FLUPENTHIXOL	1
	METRONIDAZOLE	1
	NORELGESTROMIN	1
	SERTRALINE	2
	SOLIFENACIN	1
2017	CITALOPRAM	2
	MEMANTINE	1
	SERTRALINE	1
2018	SERTRALINE	1
2019	FLUOXETINE	1
	LISDEXAMFETAMINE	1
	METHYLPHENIDATE	1
	SERTRALINE	1
2020	CANDESARTAN	1
	DULOXETINE	1
	ETHINYLESTRADIOL	1
	LEVONORGESTREL	1
	LISINOPRIL	1
	RISPERIDONE	1
	TERIPARATIDE	1
	ULIPRISTAL	1
	VENLAFAXINE	1
2021	ARIPIPRAZOLE	1
	ChAdOx1 nCoV-19	2
	CIPROFLOXACIN	1
	CITALOPRAM	2
	ESTRADIOL	1
	FLUCLOXACILLIN	1
	OESTRIOL	1
	PAROXETINE	1
	SERTRALINE	2
	TOZINAMERAN	2
	TRAZODONE	1
2022	ARIPIPRAZOLE	1
	DONEPEZIL	1
	ELASOMERAN	1
	OESTRIOL	1
	TOZINAMERAN	1
2023	DIAZEPAM	1
	DOXYCYCLINE	1
	LISDEXAMFETAMINE	1
	MEMANTINE	1
2024	CLONAZEPAM	1
2025	ARIPIPRAZOLE	1
	FLUOXETINE	1
	LINAGLIPTIN	1
	PRAMIPEXOLE	1
	TIRZEPATIDE	1

Secondary information

Type

Written question

Reference

HL11548

Session

2024-26

Subjects

Sexual dysfunction Yellow card scheme

Contains statistics

Yes

Link

View this Written question on www.parliament.uk